advisorsecurities master

APVOAptevo Therapeutics Inc

CSNasdaq (XNAS)·USD

Identity

Security key
11826
Ticker
APVO
Type
CSCommon Stock
Exchange
Nasdaq(XNAS)
Venue group
NASDAQ
Operating MIC
XNAS
Market
stocks
Locale
us
Currency
USD
Listed
2016-07-20
Round lot
100
Active
Yes
Last seen in a load
2026-08-14 20:49
Vendor updated
2026-08-13 06:09
Ticker root / suffix
APVO

Detail

Enriched 2026-08-14 20:47

Market cap
$5,312,807.5
Shares outstanding (class)
1,517,945
Shares outstanding (weighted)
1,517,945
SIC
2834 PHARMACEUTICAL PREPARATIONS
Employees
33
Location
SEATTLE, WA
Description

Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, CD3xCD123, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.

Market cap and share counts drift.

Funds holding this security

Identifiers

Classification

Fund data